{"id":"rotavirus-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":{"setId":"f3182470-1965-4e20-dbaf-e3506f893ea5","title":"ROTARIX (ROTAVIRUS VACCINE, LIVE, ORAL) SOLUTION [GLAXOSMITHKLINE BIOLOGICALS SA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains live attenuated rotavirus strains that replicate in the intestinal tract, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and neutralize wild-type rotavirus upon natural exposure, preventing or reducing the severity of rotavirus-induced diarrhea and dehydration in infants and young children.","oneSentence":"Rotavirus vaccine stimulates the immune system to produce antibodies and cellular immunity against rotavirus, preventing infection and severe gastroenteritis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:21.483Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of rotavirus gastroenteritis in infants and young children"}]},"trialDetails":[{"nctId":"NCT06950645","phase":"PHASE1","title":"The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-03-27","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT06485258","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2024-08-06","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06962904","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2025-07-07","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT01871038","phase":"","title":"Effectiveness of Monovalent Rotavirus Vaccine (RV1)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2009-07","conditions":"Rotavirus, Acute Gastroenteritis","enrollment":362},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT03313128","phase":"","title":"SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-10-05","conditions":"Rotavirus Infections, Environmental Enteric Dysfunction, Enteric Infections","enrollment":261},{"nctId":"NCT05850364","phase":"PHASE3","title":"A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-05-22","conditions":"Poliomyelitis, Polio","enrollment":1442},{"nctId":"NCT06079606","phase":"","title":"The Effects of Antibiotic Exposure in Early Infancy on Vaccine Responses","status":"ACTIVE_NOT_RECRUITING","sponsor":"Landspitali University Hospital","startDate":"2022-09-10","conditions":"Immune Responses, Antibiotic Treatment","enrollment":200},{"nctId":"NCT06331156","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-03-22","conditions":"Gastroenteritis","enrollment":400},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06967272","phase":"PHASE2","title":"PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-01-20","conditions":"Rotavirus Gastroenteritis","enrollment":400},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06200844","phase":"PHASE3","title":"The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bharat Biotech International Limited","startDate":"2023-07-07","conditions":"Rotavirus Infection of Children","enrollment":5800},{"nctId":"NCT04658914","phase":"PHASE2","title":"Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2021-04-15","conditions":"Diarrhea, Diarrhea Rotavirus","enrollment":720},{"nctId":"NCT06025695","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-09-01","conditions":"Gastroenteritis","enrollment":2000},{"nctId":"NCT01375647","phase":"PHASE3","title":"Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2011-05","conditions":"Rotavirus Diarrhea, Vaccine Virus Shedding, Tropical Enteropathy","enrollment":700},{"nctId":"NCT06882070","phase":"","title":"ROTA-biotic: Measuring the Impact of Rotavirus Vaccines on Paediatric Antibiotic Usage","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-05-04","conditions":"Rotavirus Gastroenteritis, Rotavirus Vaccines, Antimicrobial Resistance (AMR)","enrollment":1600},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT05621655","phase":"PHASE2","title":"Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-01-08","conditions":"Rotavirus Infections, Rotavirus Gastroenteritis","enrollment":1512},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06350058","phase":"PHASE1","title":"Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-08-03","conditions":"Healthy Volunteers","enrollment":375},{"nctId":"NCT02941107","phase":"PHASE4","title":"Optimising Rotavirus Vaccine in Aboriginal Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Telethon Kids Institute","startDate":"2018-03-27","conditions":"Viral Gastroenteritis Due to Rotavirus","enrollment":1000},{"nctId":"NCT06080906","phase":"PHASE2","title":"Phase II Clinical Trial of the Inactivated Rotavirus Vaccine","status":"UNKNOWN","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-10-20","conditions":"Rotavirus Infections, Diarrhea","enrollment":600},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT04185545","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2020-10-30","conditions":"Rotavirus Gastroenteritis","enrollment":1400},{"nctId":"NCT01321216","phase":"","title":"Rotavirus Burden and Genotypes in a Sentinel Hospital Surveillance System in Lebanon","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2011-12","conditions":"Gastroenteritis, Dehydration","enrollment":1555},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT02145000","phase":"PHASE3","title":"Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger","status":"COMPLETED","sponsor":"Epicentre","startDate":"2014-06","conditions":"Severe Rotavirus Gastroenteritis","enrollment":6586},{"nctId":"NCT06004258","phase":"NA","title":"Reduction of Pain in Childhood Vaccination in the Primary Care Nurse Vaccination Consultation","status":"COMPLETED","sponsor":"Hospital Universitario Virgen Macarena","startDate":"2022-06-21","conditions":"Pain","enrollment":495},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT04031846","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-04","conditions":"Pneumococcal Infections","enrollment":1184},{"nctId":"NCT05958771","phase":"PHASE3","title":"The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E","status":"UNKNOWN","sponsor":"University of Chile","startDate":"2023-07-06","conditions":"Rotavirus Gastroenteritis","enrollment":5800},{"nctId":"NCT03483116","phase":"PHASE2","title":"A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2018-06-15","conditions":"Rotavirus Infections","enrollment":711},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT04344054","phase":"PHASE2","title":"Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2021-02-22","conditions":"Rotavirus Vaccine","enrollment":850},{"nctId":"NCT03587389","phase":"PHASE4","title":"Response to Rotavirus Vaccine in Infants in Ho Chi Minh City in Vietnam","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2019-03-19","conditions":"Rotavirus, Diarrhea","enrollment":818},{"nctId":"NCT02902445","phase":"","title":"Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2017-02-28","conditions":"Gastroenteritis, Acute Gastroenteritis","enrollment":611},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT05212935","phase":"","title":"A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2022-05","conditions":"Vaccination, Rotavirus Infections, Meningococcal Infections","enrollment":2000},{"nctId":"NCT03954743","phase":"PHASE3","title":"Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-19","conditions":"Infections, Rotavirus","enrollment":1351},{"nctId":"NCT01273077","phase":"","title":"Evaluation of Universal Rotavirus Vaccination Program","status":"COMPLETED","sponsor":"Dalhousie University","startDate":"2010-12","conditions":"Gastrointestinal Diseases","enrollment":12705},{"nctId":"NCT00880698","phase":"PHASE2","title":"Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-12","conditions":"HIV Infection, Rotavirus Infection","enrollment":202},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT05037435","phase":"PHASE3","title":"Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.","status":"COMPLETED","sponsor":"Limited Liability Company Pharm Aid","startDate":"2018-06-25","conditions":"Rotavirus Infections, Rotavirus Vaccines","enrollment":40},{"nctId":"NCT05032391","phase":"PHASE3","title":"Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization","status":"COMPLETED","sponsor":"Limited Liability Company Pharm Aid","startDate":"2019-02-22","conditions":"Rotavirus Infection","enrollment":100},{"nctId":"NCT04010448","phase":"PHASE3","title":"A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India","status":"UNKNOWN","sponsor":"PATH","startDate":"2019-10-10","conditions":"Rotavirus Infection of Children","enrollment":8200},{"nctId":"NCT04819412","phase":"PHASE3","title":"To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2015-03-20","conditions":"Rotavirus Gastroenteritis","enrollment":1975},{"nctId":"NCT01633190","phase":"","title":"Canadian Rotavirus Surveillance Through the Immunization Monitoring Program Active (IMPACT)","status":"UNKNOWN","sponsor":"Canadian Paediatric Society","startDate":"2012-03","conditions":"Viral Gastroenteritis Due to Rotavirus","enrollment":2500},{"nctId":"NCT00353366","phase":"","title":"To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-16","conditions":"Infections, Rotavirus, Rotavirus Vaccines","enrollment":1439},{"nctId":"NCT00439660","phase":"PHASE1, PHASE2","title":"Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2006-12","conditions":"Diarrhea","enrollment":540},{"nctId":"NCT03703336","phase":"PHASE3","title":"Phase III Study of Liquid Formulation of ROTAVIN","status":"COMPLETED","sponsor":"Center for Research and Production of Vaccines and Biologicals, Vietnam","startDate":"2019-03-16","conditions":"Diarrhea, Diarrhea Rotavirus","enrollment":825},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT03602053","phase":"PHASE2, PHASE3","title":"Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2019-01-22","conditions":"Diarrhea, Diarrhea Rotavirus","enrollment":450},{"nctId":"NCT04626856","phase":"PHASE1","title":"Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-12-03","conditions":"Rotavirus Infection","enrollment":32},{"nctId":"NCT02141204","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-02-20","conditions":"Rotavirus","enrollment":451},{"nctId":"NCT00263666","phase":"PHASE2","title":"A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-16","conditions":"Infections, Rotavirus","enrollment":100},{"nctId":"NCT04596696","phase":"PHASE3","title":"Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac in Healthy Infants in Vietnam","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2017-12-20","conditions":"Rotavirus Gastroenteritis","enrollment":360},{"nctId":"NCT01896596","phase":"PHASE4","title":"Hepatitis B Vaccination in Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-07","conditions":"Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease","enrollment":300},{"nctId":"NCT02992197","phase":"PHASE4","title":"The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2017-06-12","conditions":"Rotavirus Infection, Vaccine Response Impaired, Vaccine Virus Shedding","enrollment":220},{"nctId":"NCT02914184","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-27","conditions":"Infections, Rotavirus, Rotavirus Vaccines","enrollment":1612},{"nctId":"NCT02646891","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2016-02-15","conditions":"Healthy","enrollment":618},{"nctId":"NCT00750893","phase":"","title":"Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-02","conditions":"Infections, Rotavirus","enrollment":3111},{"nctId":"NCT00969228","phase":"PHASE4","title":"Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-25","conditions":"Infections, Rotavirus, Rotavirus Vaccines","enrollment":684},{"nctId":"NCT00489554","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":230},{"nctId":"NCT01177826","phase":"","title":"Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-23","conditions":"Infections, Rotavirus, Rotavirus Vaccines","enrollment":643},{"nctId":"NCT00970307","phase":"PHASE2","title":"Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-13","conditions":"Tetanus, Diphtheria, Haemophilus Influenzae Type b","enrollment":421},{"nctId":"NCT00432380","phase":"PHASE2","title":"A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-09","conditions":"Infections, Rotavirus, Rotavirus Vaccines","enrollment":375},{"nctId":"NCT00480324","phase":"PHASE3","title":"Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-19","conditions":"Infections, Rotavirus, Rotavirus Vaccines","enrollment":765},{"nctId":"NCT00140673","phase":"PHASE3","title":"A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08-05","conditions":"Infections, Rotavirus","enrollment":63227},{"nctId":"NCT00385320","phase":"PHASE2","title":"Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-05-31","conditions":"Infections, Rotavirus","enrollment":2640},{"nctId":"NCT01309646","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-04","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":454},{"nctId":"NCT02096263","phase":"PHASE3","title":"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-16","conditions":"Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b","enrollment":585},{"nctId":"NCT02907216","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-16","conditions":"Rotavirus","enrollment":292},{"nctId":"NCT01026779","phase":"","title":"Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island","status":"COMPLETED","sponsor":"Lifespan","startDate":"2009-07","conditions":"Rotavirus Gastroenteritis","enrollment":803},{"nctId":"NCT04123119","phase":"NA","title":"Development of a Live Attenuated Rotavirus Vaccine as a Human Infection Challenge Model","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2019-01-22","conditions":"Diarrhoeal Disease","enrollment":22},{"nctId":"NCT03507738","phase":"PHASE1","title":"Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-07-03","conditions":"Healthy","enrollment":110},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT03462108","phase":"PHASE1","title":"Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2018-04-09","conditions":"Safety Issues","enrollment":100},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT03367559","phase":"PHASE3","title":"Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam","status":"UNKNOWN","sponsor":"Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products","startDate":"2018-02-08","conditions":"Rotavirus Infections","enrollment":360},{"nctId":"NCT01700621","phase":"PHASE4","title":"Coadministration of Measles-rubella and Rotavirus Vaccines","status":"COMPLETED","sponsor":"PATH","startDate":"2013-01","conditions":"Measles Antibody Seroconversion, Rubella Antibody Seroconversion, Rotavirus Geometric Mean Titer (GMT)","enrollment":482},{"nctId":"NCT01764256","phase":"PHASE1","title":"A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-12","conditions":"Rotavirus Infection","enrollment":48},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT00875641","phase":"","title":"Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-20","conditions":"Infections, Rotavirus","enrollment":390659}],"_emaApprovals":[],"_faersSignals":[{"count":22,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"},{"count":9,"reaction":"INCORRECT DOSE ADMINISTERED"},{"count":8,"reaction":"ATRIAL SEPTAL DEFECT"},{"count":8,"reaction":"CHOLESTASIS"},{"count":8,"reaction":"EXPOSURE VIA BREAST MILK"},{"count":8,"reaction":"HYPOVITAMINOSIS"},{"count":8,"reaction":"LIVER INJURY"},{"count":8,"reaction":"TRANSAMINASES INCREASED"},{"count":7,"reaction":"DIARRHOEA"},{"count":7,"reaction":"LOW BIRTH WEIGHT BABY"}],"_approvalHistory":[],"publicationCount":2837,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rotarix","brazilian rotavirus vaccine","RotaTeq® Rotarix®","Rotarix™ or RotaTeq™","RotaTeq/ROTARIX"],"phase":"marketed","status":"active","brandName":"Rotavirus vaccine","genericName":"Rotavirus vaccine","companyName":"PATH","companyId":"path","modality":"Biologic","firstApprovalDate":"","aiSummary":"Rotavirus vaccine stimulates the immune system to produce antibodies and cellular immunity against rotavirus, preventing infection and severe gastroenteritis. Used for Prevention of rotavirus gastroenteritis in infants and young children.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"Rotashield","application_number":"EMEA/H/C/000192"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Rotashield","application_number":null}],"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}